ATE221883T1 - Substituierte 4-(1h-benzimidazol-2-yl)(1, 4)diazepane für die behandlung von allergischen krankheiten - Google Patents

Substituierte 4-(1h-benzimidazol-2-yl)(1, 4)diazepane für die behandlung von allergischen krankheiten

Info

Publication number
ATE221883T1
ATE221883T1 AT96944267T AT96944267T ATE221883T1 AT E221883 T1 ATE221883 T1 AT E221883T1 AT 96944267 T AT96944267 T AT 96944267T AT 96944267 T AT96944267 T AT 96944267T AT E221883 T1 ATE221883 T1 AT E221883T1
Authority
AT
Austria
Prior art keywords
diazepans
benzimidazole
substituted
treatment
allergy diseases
Prior art date
Application number
AT96944267T
Other languages
English (en)
Inventor
John Michael Kane
George Daniel Maynard
Timothy Paul Burkholder
Larry Don Bratton
Christopher Robin Dalton
Braulio Santiago
Elizabeth Mary Kudlacz
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE221883T1 publication Critical patent/ATE221883T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96944267T 1995-12-20 1996-12-04 Substituierte 4-(1h-benzimidazol-2-yl)(1, 4)diazepane für die behandlung von allergischen krankheiten ATE221883T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58000495A 1995-12-20 1995-12-20
US73641196A 1996-10-24 1996-10-24
PCT/US1996/019524 WO1997022604A1 (en) 1995-12-20 1996-12-04 Novel substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases

Publications (1)

Publication Number Publication Date
ATE221883T1 true ATE221883T1 (de) 2002-08-15

Family

ID=27077922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944267T ATE221883T1 (de) 1995-12-20 1996-12-04 Substituierte 4-(1h-benzimidazol-2-yl)(1, 4)diazepane für die behandlung von allergischen krankheiten

Country Status (19)

Country Link
EP (1) EP0874843B1 (de)
JP (1) JP2000500772A (de)
KR (1) KR20000064487A (de)
CN (1) CN1080262C (de)
AR (1) AR005120A1 (de)
AT (1) ATE221883T1 (de)
AU (1) AU707914B2 (de)
BR (1) BR9612074A (de)
CA (1) CA2241827C (de)
DE (1) DE69622889T2 (de)
DK (1) DK0874843T3 (de)
ES (1) ES2177827T3 (de)
IL (1) IL125002A0 (de)
MX (1) MX9804991A (de)
NO (1) NO316932B1 (de)
NZ (1) NZ325581A (de)
PT (1) PT874843E (de)
TW (1) TW335395B (de)
WO (1) WO1997022604A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194406B1 (en) * 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
EP1747198B1 (de) 2004-05-07 2008-06-04 Janssen Pharmaceutica N.V. Adamantyl pyrrolidin-2-on-derivate als 11-beta hydroxysteroid dehydrogenas inhibitoren
CA2565630C (en) 2004-05-07 2013-05-28 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
MY141198A (en) 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
CN101300005B (zh) 2004-08-30 2013-05-01 詹森药业有限公司 作为11-β羟类固醇脱氢酶抑制剂的N-2金刚烷基-2-苯氧基-乙酰胺衍生物
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
CN105646306B (zh) * 2015-12-11 2020-06-30 广东莱佛士制药技术有限公司 一种4-甲硫基苯乙酸的制备方法
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1994026735A1 (en) * 1993-05-06 1994-11-24 Merrell Dow Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
CA2161876A1 (en) * 1993-05-20 1994-12-08 Den-Ichi Momose 1-(2-benzimidazolyl)-1,5-diazacyclooctane compounds
CN1067385C (zh) * 1994-08-25 2001-06-20 默里尔药物公司 用于治疗变应性疾病的新的取代的哌啶类化合物

Also Published As

Publication number Publication date
DE69622889D1 (de) 2002-09-12
KR20000064487A (ko) 2000-11-06
DK0874843T3 (da) 2002-11-25
CA2241827C (en) 2002-04-30
EP0874843B1 (de) 2002-08-07
NO982867L (no) 1998-08-19
CN1080262C (zh) 2002-03-06
NZ325581A (en) 2000-03-27
WO1997022604A1 (en) 1997-06-26
CN1207097A (zh) 1999-02-03
AU707914B2 (en) 1999-07-22
NO316932B1 (no) 2004-06-28
HK1017684A1 (en) 1999-11-26
AR005120A1 (es) 1999-04-14
PT874843E (pt) 2002-12-31
ES2177827T3 (es) 2002-12-16
DE69622889T2 (de) 2003-04-10
NO982867D0 (no) 1998-06-19
JP2000500772A (ja) 2000-01-25
CA2241827A1 (en) 1997-06-26
TW335395B (en) 1998-07-01
BR9612074A (pt) 1999-03-30
EP0874843A1 (de) 1998-11-04
MX9804991A (es) 1998-09-30
AU1411997A (en) 1997-07-14
IL125002A0 (en) 1999-01-26

Similar Documents

Publication Publication Date Title
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
EP0792137A4 (de) Pilzhemmende behandlung für die nägel
DE69829558D1 (de) Sulfonamide für die behandlung von störungen durch endothelin vermittelt
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE235191T1 (de) Markraumnagel für die versorgung von frakturen der hüfte
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DE69008342D1 (de) Orthese für die Behandlung von Schienbeinverdrehungen bei Kindern.
DE69636828D1 (de) Wässrige Polyorganosiloxanemulsion für die Behandlung von Textilprodukten
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE59801385D1 (de) Durchlaufanlage für die behandlung von werkstücken
FI974640A0 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
ATE330604T1 (de) Behandlung von manischen erkrankungen
DE69800092D1 (de) Substituierte 4-(6-fluor-[1H]-indol-3-yl)1,2,3,6-Tetrahydropyridin-Derivate für die Behandlung von ZNS-Störungen
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
ATE355283T1 (de) Isochroman verbindungen für die behandlung von cns-krankheiten
DE69917445D1 (de) Reinigung von carboxaldehyd
DE69607443D1 (de) Zwischenprodukte und ihre Anwendung für die Herstellung von N,N'-überbrückten Bisindolylmaleimiden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee